Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Verve Therapeutics is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). Verve is advancing its lead product candidate, VERVE-101, in clinical trials for patients with heterozygous familial hypercholesterolemia (HeFH).
The headquarters serves as the central hub for Verve's research and development, clinical operations, corporate administration, and strategic decision-making, driving the innovation in gene editing therapies.
Located within a modern life sciences campus, providing access to state-of-the-art laboratory and office facilities designed to support cutting-edge biotechnology research and development.
Verve fosters a collaborative, innovative, and science-driven work culture. Employees are often mission-oriented, focused on tackling significant challenges in cardiovascular medicine with a sense of urgency and strong patient focus.
The Cambridge headquarters strategically positions Verve within one of the world's leading biotechnology ecosystems, facilitating access to top talent, renowned academic and research institutions, and industry collaborations.
Verve Therapeutics is establishing a global presence primarily focused on advancing its clinical development programs. This includes conducting clinical trials in North America and Europe, engaging with international regulatory authorities like the FDA, EMA, and MHRA, and forming strategic collaborations with research institutions and pharmaceutical partners worldwide to accelerate the development and potential delivery of its gene editing medicines for cardiovascular disease to patients globally.
200 Cambridgepark Drive, Suite 4100
Cambridge
Massachusetts
USA
Address: c/o HMR, Cumberland Avenue, Park Royal, London, NW10 7EW, UK
Facilitates the execution of clinical studies for Verve's gene editing therapies in the UK and engagement with local regulatory bodies, playing a role in the company's global drug development strategy.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Verve Therapeutics' leadership includes:
Verve Therapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months, Verve Therapeutics has significantly strengthened its executive leadership by appointing a new Chief Financial Officer, a new Chief Business Officer, and a new Chief Technology Officer. These changes reflect the company's strategic focus on advancing its clinical pipeline and preparing for future growth.
Discover the tools Verve Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Verve Therapeutics commonly utilizes the email format combining the first initial and full last name of an employee. This is a standard approach for many companies in the biotechnology sector for professional communication.
[first_initial][last]@vervetx.com
Format
jdoe@vervetx.com
Example
85%
Success rate
GlobeNewswire • May 9, 2024
Verve Therapeutics announced its Q1 2024 financial results, offering updates on its gene editing pipeline, including VERVE-101, VERVE-102, and VERVE-201. The company emphasized its commitment to advancing clinical trials and research for cardiovascular disease treatments....more
Verve Therapeutics Press Release • May 7, 2024
Verve shared new preclinical data for VERVE-102, an in vivo base editing medicine targeting the PCSK9 gene. The data, presented at ASGCT, showed robust and durable LDL-C lowering in non-human primates, supporting its potential as a treatment for ASCVD....more
Verve Therapeutics Press Release • February 20, 2024
Verve Therapeutics announced Kristen Fortney, Ph.D., as its new Chief Technology Officer, effective March 4, 2024. Dr. Fortney brings deep expertise in bioinformatics, machine learning, and technology strategy to enhance Verve's gene editing platform capabilities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Verve Therapeutics, are just a search away.